Docefrez (docetaxel) may be a cancer medication that interferes with the expansion and unfold of cancer cells within the body.

Docefrez is employed to treat carcinoma, non-small cell carcinoma, and adenocarcinoma.

Docefrez may be used for functions unlisted during this medication guide.

Submit your review

Create your own review

Average rating:  
 0 reviews
  • Docefrez, Taxotere
  • Get emergency medical help if you have signs of an allergic reaction to Docefrez: hives, red skin rash; difficult breathing; feeling like you might pass out; swelling of your face, lips, tongue, or throat.

    Call your doctor at once if you have:

    sudden vision problems;
    extreme weakness, severe vomiting or diarrhea;
    redness or peeling of the skin on your hands and feet;
    numbness, burning pain, or tingly feeling;
    a feeling of being drunk - confusion, stumbling, extreme drowsiness;
    signs of infection - fever, swollen gums, painful mouth sores, pain when swallowing, skin sores, cold or flu symptoms, cough, trouble breathing;
    low red blood cells - pale skin, feeling light-headed or short of breath, rapid heart rate, trouble concentrating;
    low platelets in your blood - easy bruising, unusual bleeding (nose, mouth, vagina, or rectum), purple or red pinpoint spots under your skin;
    fluid retention - little or no urinating, swelling of your ankles or feet, rapid weight gain; or
    liver problems - upper stomach pain, loss of appetite, dark urine, clay-colored stools, jaundice (yellowing of the skin or eyes).
    Older adults may be more likely to have side effects from this medicine.

    Common Docefrez side effects may include:

    mild weakness;
    altered sense of taste;
    nausea, vomiting, loss of appetite;
    constipation, diarrhea;
    temporary hair loss;
    muscle pain;
    mild skin rash; or
    fingernail or toenail changes.
  • Prostate Cancer For hormone-refractory metastatic prostate cancer, the recommended dose of DOCEFREZ is 75 mg/m2 every 3 weeks as a 1 hour intravenous infusion. Prednisone 5 mg orally twice daily is administered continuously. Breast Cancer: For locally advanced or metastatic breast cancer after failure of prior chemotherapy, the recommended dose of DOCEFREZ is 60 mg/m2 to 100 mg/m2 administered intravenously over 1 hour every 3 weeks.